1287 related articles for article (PubMed ID: 11176980)
1. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
Bressler NM;
Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
[TBL] [Abstract][Full Text] [Related]
3. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
Verteporfin In Photodynamic Therapy Study Group
Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
[TBL] [Abstract][Full Text] [Related]
4. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
Blinder KJ; Blumenkranz MS; Bressler NM; Bressler SB; Donato G; Lewis H; Lim JI; Menchini U; Miller JW; Mones JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld P; Schachat AP; Schmidt-Erfurth U; Sickenberg M; Singerman LJ; Slakter JS; Strong HA; Virgili G; Williams GA
Ophthalmology; 2003 Apr; 110(4):667-73. PubMed ID: 12689884
[TBL] [Abstract][Full Text] [Related]
5. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
[TBL] [Abstract][Full Text] [Related]
6. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
Verteporfin in Photodynamic Therapy Study Group
Ophthalmology; 2001 May; 108(5):841-52. PubMed ID: 11320011
[TBL] [Abstract][Full Text] [Related]
8. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
Blumenkranz MS; Bressler NM; Bressler SB; Donati G; Fish GE; Haynes LA; Lewis H; Miller JW; Monés JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Schachat AP; Schmidt-Erfurth U; Sickenburg M; Singerman LJ; Slakter JS; Strong A; Vannier S;
Arch Ophthalmol; 2002 Oct; 120(10):1307-14. PubMed ID: 12365909
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
Barbazetto I; Burdan A; Bressler NM; Bressler SB; Haynes L; Kapetanios AD; Lukas J; Olsen K; Potter M; Reaves A; Rosenfeld P; Schachat AP; Strong HA; Wenkstern A; ;
Arch Ophthalmol; 2003 Sep; 121(9):1253-68. PubMed ID: 12963608
[TBL] [Abstract][Full Text] [Related]
10. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
Kaiser PK;
Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
[TBL] [Abstract][Full Text] [Related]
11. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Japanese Age-Related Macular Degeneration Tial (JAT) Study Group
Am J Ophthalmol; 2003 Dec; 136(6):1049-61. PubMed ID: 14644215
[TBL] [Abstract][Full Text] [Related]
12. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
Pieramici DJ; Bressler SB; Koester JM; Bressler NM
Arch Ophthalmol; 2006 May; 124(5):660-4. PubMed ID: 16682587
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study.
Rosenfeld PJ; Saperstein DA; Bressler NM; Reaves TA; Sickenberg M; Rosa RH; Sternberg P; Aaberg TM; Aaberg TM;
Ophthalmology; 2004 Sep; 111(9):1725-33. PubMed ID: 15350329
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.
Saperstein DA; Rosenfeld PJ; Bressler NM; Rosa RH; Sickenberg M; Sternberg P; Aaberg TM; Aaberg TM; Reaves TA;
Ophthalmology; 2002 Aug; 109(8):1499-505. PubMed ID: 12153802
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
Miller JW; Schmidt-Erfurth U; Sickenberg M; Pournaras CJ; Laqua H; Barbazetto I; Zografos L; Piguet B; Donati G; Lane AM; Birngruber R; van den Berg H; Strong A; Manjuris U; Gray T; Fsadni M; Bressler NM; Gragoudas ES
Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
[TBL] [Abstract][Full Text] [Related]
16. [Photodynamic therapy in age-related macular degeneration--results of one year observation].
Wykrota H; Gierek-Łapińska A
Klin Oczna; 2002; 104(3-4):239-43. PubMed ID: 12608309
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
Verteporfin Roundtable Participants
Retina; 2005; 25(2):119-34. PubMed ID: 15689800
[TBL] [Abstract][Full Text] [Related]
19. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.
Incorvaia C; Campa C; Parmeggiani F; Menzione M; D'Angelo S; Della Corte M; Rinaldi M; Romano M; Dell'omo R; Costagliola C
Retina; 2008 Feb; 28(2):289-97. PubMed ID: 18301052
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
